ByTrending Posts
PostEra and Pfizer’s AI Lab Accelerates Drug Discovery,…
Boston – March 27, 2024 Advancing AI-Driven Drug Discovery PostEra has provided an update on the progress of…
BenevolentAI Reports Positive Phase Ia Results for AI-Designed…
London, UK – March 25, 2024 Clinical Milestone Achieved BenevolentAI has announced positive safety results from its Phase…
Relation Therapeutics Secures $35 Million in New Seed…
London, UK – March 14, 2024 Relation Therapeutics, a biotechnology company at the forefront of computational and experimental…
Saama and Pfizer Deepen AI Partnership to Accelerate…
Expanded multi-year agreement will scale AI-powered data solutions across Pfizer’s R&D portfolio. Campbell, CA – February 12, 2024…
Cervical Cancer Detection AI: How Is BD Applying…
BD and Techcyte Partner on AI-Based Application to Modernize Cervical Cancer Screening FRANKLIN LAKES, N.J. & OREM, Utah…
Merck and Variational AI Collaborate to Advance AI-Driven…
Vancouver, BC – January 25, 2024 Variational AI, a leader in generative AI drug discovery, has announced a…
AI Meets Neuroscience: BullFrog AI and LIBD Unlock…
Gaithersburg, Md – Jan 17 2024 BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW), a technology-enabled drug development company…
Nvidia Expands AI Drug Discovery with Amgen and…
JPM Conference, January 8, 2024 Nvidia is advancing its footprint in AI-powered drug discovery through new collaborations with…
Insilico Medicine Achieves Milestone with Positive Phase I…
CAMBRIDGE, Massachusetts, January 7, 2024 Insilico Medicine, a clinical-stage leader in generative AI-driven drug discovery and development, has…
Trending Posts
Latest Stories
How Did Johnson & Johnson Navigate 2025 and What Lies Ahead for 2026?
Johnson & Johnson concluded 2025 with a combination of resilient portfolio performance, strategic execution, and…
How Did Novartis’ 2025 Deals Shape Its Strategic Direction and What Might They Signal for 2026?
Novartis’ deal activity in 2025 reflected a deliberate and strategic effort to strengthen its scientific…
How Did Novartis Navigate 2025 and What’s Ahead for 2026?
In 2025, Novartis demonstrated resilience and strategic focus, balancing strong performance in its core franchises…
How Did AbbVie’s 2025 Deals Shape Its Year, and What Do They Signal for Growth in 2026?
NORTH CHICAGO, IL — As 2025 concludes, AbbVie Inc. reflects on a year of strategic…
Gallery
